Which option tends to fit which patient

A useful first split is not a full patient-by-patient grid, but the broad trade-off between speed, durability and how established the evidence is. In knee osteoarthritis, these injections are mainly used to ease pain and improve function for a period of time rather than serve as a proven way to undo established joint wear.

• Cortisone usually sits at the fast-relief end. AAOS guidance frames knee steroid injections as mainly short term, and NHS patient information says hydrocortisone joint injections often help for around 2 months and sometimes a few months, so they tend to fit a painful flare or a short window needed for travel or rehabilitation.
• PRP usually sits at the slower-onset, potentially longer-lasting end. In a 40-patient randomised study of Kellgren-Lawrence II–III knee OA, PRP and triamcinolone both helped early, but only PRP maintained significant improvement through 1 year; mild transient synovitis was common in the first week after PRP.
• Hyaluronic acid is better thought of as a symptom-control option with many versions rather than one single treatment. A review of 38 RCTs found major variation in product type and dosing, from single injections to 3–5 shot courses, which helps explain why guideline support is mixed; the 2021 AAOS guideline says it is not recommended for routine use.
• Arthrosamid is the main single-injection hydrogel option. In a 49-patient open-label knee OA study, a 6 mL ultrasound-guided injection improved WOMAC scores through 52 weeks, with 62.2% meeting responder criteria at 1 year. It is generally positioned for mild-to-moderate symptomatic knee OA, with a smaller and less mature evidence base than older injectables.

When Arthrosamid is a reasonable knee option

The best fit is usually a painful knee with mild-to-moderate osteoarthritis, where the aim is longer symptom control without moving straight to surgery. Arthrosamid is a single intra-articular polyacrylamide hydrogel injection, so its practical appeal is simple: one treatment episode rather than a 3- to 5-injection course or regular repeat visits. It is less likely to suit inflammatory arthritis, an active infection concern, or severe bone-on-bone wear, where knee replacement is often the more realistic option.

Its main difference is that it is designed to stay in the knee. As a non-biodegradable hydrogel, it blends with the synovial lining to form a flexible cushioning layer rather than fading quickly. Published knee data have shown encouraging symptom improvement at 12 months, and a systematic review of 463 reported patients found continuation data suggesting benefit can extend to 2 years. For some patients, that one-off format and possible durability are the strongest reasons to consider it.

The trade-off is that permanence cuts both ways. The Arthrosamid evidence base is still smaller and less mature than for older knee injections, with fewer strong comparative studies. Although published follow-up has not reported long-lasting adverse events in the available knee studies, clinicians still discuss theoretical concerns about foreign-body inflammation, migration, and the fact that revision may be more awkward if trouble occurs later. That makes Arthrosamid a selective knee option rather than a routine default.

How hyaluronic acid choices differ

The memorable point with hyaluronic acid in the knee is that it is not one uniform treatment. It is viscosupplementation for symptom control, not cartilage repair, and the reason patients hear conflicting messages is simple: studies often compare quite different gels, in quite different schedules, in quite different grades of knee osteoarthritis.

One practical decision point is the regimen. Some knee products are given as one injection, while others are given weekly as a 3- to 5-injection course. Head-to-head reviews have not shown a consistent patient-reported advantage for more injections, so a longer course does not automatically mean a better result. At the same time, a placebo-controlled meta-analysis found the strongest pain signal with 2 to 4 injections, whereas single-injection studies did not show significant pain benefit at 3 or 6 months, and 5 or more injections were linked with more treatment-related adverse events. That is one reason the HA literature can look contradictory.

The second variable is the gel itself. Reviews of 38 randomised trials show marked variation in molecular weight and product design, including cross-linking. The broad pattern is that high- and ultra-high-molecular-weight HA appears more promising than low-molecular-weight HA for pain reduction at around 4 to 6 months, although broader reviews still describe the overall evidence as mixed rather than uniform.

In knee practice, HA tends to make most sense in early-to-moderate OA—often Kellgren-Lawrence grades 1 to 3—when the joint is still mechanically salvageable and the aim is to defer surgery. Published reviews also suggest that repeat cycles can be effective and generally safe, but the size of benefit still seems to depend on the specific product and the patient in front of the clinician.

PRP or cortisone for early knee osteoarthritis

In early knee osteoarthritis, the first practical split between corticosteroid and PRP is timing. A steroid injection is usually chosen when the knee is sore now and fast symptom control matters most. NHS patient guidance on hydrocortisone joint injections says benefit often lasts for around 2 months, and sometimes a few months. PRP, by contrast, is not usually framed as an instant-relief option; public clinical guidance notes that improvement may take a few weeks to become noticeable.

The medium-term evidence currently gives PRP the stronger signal in mild-to-moderate knee OA. In a randomised study of 40 patients with Kellgren-Lawrence II–III disease, both PRP and triamcinolone improved pain and function at 1 week and through 5 weeks, but only PRP maintained significant improvement through 1 year. No serious adverse effects were reported, although 75% of the PRP group had mild transient synovitis in the first week. A network meta-analysis looking at outcomes from 6 months onwards also found PRP ranked highest overall for pain and function, while corticosteroid ranked close to placebo.

That makes the knee decision fairly concrete. Cortisone still has a legitimate role during a painful flare, before travel, or when inflammation needs settling enough to restart physiotherapy. PRP tends to fit earlier OA when a slower onset is acceptable in exchange for a better chance of longer benefit, while also accepting that PRP protocols can vary between clinics. What steroid does not look like is a durable long-term strategy for knee OA: both trial data and AAOS guidance frame intra-articular corticosteroid mainly as short-term relief rather than ongoing disease control.

What onset, recovery, and durability usually look like

For most knee injections, the immediate recovery window is usually discussed in days rather than weeks, but that does not mean the first few days feel identical. Short-lived post-injection soreness or swelling can occur after Arthrosamid, hyaluronic acid, PRP or cortisone in routine knee practice, and the published evidence is stronger on symptom scores at weeks to months than on day-by-day recovery. That is why timing is best read as a typical pattern rather than a guarantee.

• Cortisone is often the quickest. NHS guidance for hydrocortisone joint injections says benefit often lasts around 2 months, and sometimes a few months. The trade-off is that fast relief is not usually the same as durable relief.
• PRP often has the slowest start. In the 40-patient randomised knee OA trial, mild transient synovitis affected 75% of the PRP group in the first week, even though longer follow-up favoured PRP through 1 year.
• Hyaluronic acid is usually judged over several weeks and then 3 to 6 months, not by what the knee feels like the next morning. Product type and injection schedule matter, so one HA timeline does not fit every gel.
• Arthrosamid is also not an instant-result injection. In the 49-patient open-label study, outcomes improved through 52 weeks, and review data suggest benefit may continue to 2 years in some series.

In practical terms, patients are usually given product-specific aftercare by the treating clinic, and many are advised to keep activity relatively light immediately afterwards before building back to usual loading as directed. Marked swelling, fever, or pain that stays worse rather than settling over several days is a reason to contact the treating clinic.

When an injection is the wrong next step

Some painful knees are poor candidates for any osteoarthritis injection, whatever the label on the syringe. In the 38-RCT hyaluronic acid review, most patients had Kellgren-Lawrence grades 1 to 3, and the main PRP versus triamcinolone trial followed 40 patients with grade II–III disease; a truly bone-on-bone knee sits outside the group most often studied. Arthrosamid guidance also states that it is less suitable for severe bone-on-bone arthritis, where knee replacement is often more effective, and it is not intended for inflammatory arthritis. A knee with major varus or valgus malalignment, repeated giving way, or pain from the wrong diagnosis is likewise less likely to improve simply because an injection was chosen. A hot swollen knee, fever, recent infection concern, or marked locking and catching needs a different knee work-up before any routine OA injection is considered.

The wider pathway matters just as much as the syringe. Cleveland Clinic describes knee hyaluronic acid as a second-line option after first-line care has not done enough, which is a useful way to think about injections more broadly: they sit alongside exercise therapy, weight management, appropriate bracing, and, for selected knees, discussion of osteotomy or knee replacement. The important conclusion is the treatment match, not where the injection is booked: confirm what is actually driving the knee pain, then choose the pathway that fits that source.

1. [1] *Platelet rich plasma, bone marrow aspirate concentrate and hyaluronic acid injections outperform corticosteroids in pain and function scores at a minimum of 6 months as intra-articular injections for knee osteoarthritis: A systematic review and network meta-analysis*. (2024). https://doi.org/10.1016/j.arthro.2024.01.037 https://doi.org/10.1016/j.arthro.2024.01.037
2. [2] *Comparison of different molecular weights of intra-articular hyaluronic acid injections for knee osteoarthritis: A level I Bayesian network meta-analysis*. (2025). https://doi.org/10.3390/biomedicines13010175 https://doi.org/10.3390/biomedicines13010175